Elucidating How Amyloid-Beta Changes Protein Expression in AD Brain

About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
July 01, 2021 - June 30, 2024
Grant ID
A2021030S
Goals
We propose to study the functional consequences of a transcription factor complex that specifically forms in AD and deregulates protein expression in AD brain.
Summary
Aim 1: We found that the Aß1-42-induced interaction of two transcription factors is part of AD pathology. Here, we will investigate whether the formation of this complex is sufficient to dysregulate intracellular protein trafficking, and whether as a consequence Aß1-42 production is increased. Aim 2: We propose that AD-linked transcription factor interaction dysregulates the expression of genes important for the secretion of proteins in AD brain. Here, we will investigate the consequences of neuron-specific loss of one of the transcription factors in wild type mice and in an AD mouse model.
Unique and Innovative
The search for the causes of transcriptional misregulation in disease is often aimed at finding individual transcription factors, but these proteins have important functions outside of pathology and are thus problematic as drug targets. Here, we are instead focusing on an interaction between two transcription factors in AD brain that leads to pathogenic changes in gene expression. Targeting this interaction, rather than the individual transcription factors might be a novel avenue for a disease-modifying therapy in AD.
Foreseeable Benefits
The successful completion of our research proposal will establish the concept that changes in protein expression in AD can be caused by the erroneous interaction between two transcription factors rather than by changes in their levels. We expect this principle to be apply to other diseases as well, esp. Parkinson’s disease. The next step will be to investigate whether this mechanisms can be targeted therapeutically.
Related Grants
Alzheimer's Disease Research
Study of a Novel Genetic Risk Factor for Alzheimer's Disease
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Giuseppina Tesco, MD, PhD
Current Organization
Tufts University
Alzheimer's Disease Research
Uncovering How Gene Regulators Protect Neurons Against Alzheimer's
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Raffaella Nativio, PhD
Current Organization
Imperial College London
Alzheimer's Disease Research
Decoding Alzheimer’s Disease Genomes With Deep Learning
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Tatsuhiko Naito, MD, PhD
Current Organization
Icahn School of Medicine at Mount Sinai